Ras protein expression as a marker for breast cancer

Calaf,Gloria M.; Abarca‑Quinones,Jorge

doi:10.3892/ol.2016.4461

Ras protein expression as a marker for breast cancer

Authors:
- Gloria M. Calaf
- Jorge Abarca‑Quinones
View Affiliations

Affiliations: Institute for Advanced Research, Tarapacá University, Arica 1001236, Chile, School of Medicine, Saint‑Luc Hospital, IMAG Unit (IREC), University of Louvain, Brussels 1200, Belgium
Published online on: April 19, 2016 https://doi.org/10.3892/ol.2016.4461
Pages: 3637-3642
Copyright: © Calaf et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer, the most common neoplasm in women of all ages, is the leading cause of cancer-related mortality in women worldwide. Markers to help to predict the risk of progression and ultimately provide non‑surgical treatment options would be of great benefit. At present, there are no available molecular markers to predict the risk of carcinoma in situ progression to invasive cancer; therefore, all women diagnosed with this type of malignancy must undergo surgery. Breast cancer is a heterogeneous complex disease, and different patients respond differently to different treatments. In breast cancer, analysis using immunohistochemical markers remains an essential component of routine pathological examinations, and plays an import role in the management of the disease by providing diagnostic and prognostic strategies. The aim of the present study was to identify a marker that can be used as a prognostic tool for breast cancer. For this purpose, we firstly used an established breast cancer model. MCF‑10F, a spontaneously immortalized breast epithelial cell line was transformed by exposure to estrogen and radiation. MCF‑10F cells were exposed to low doses of high linear energy transfer (LET) α particles (150 keV/μm) of radiation, and subsequently cultured in the presence of 17β‑estradiol. Three cell lines were used: i) MCF‑10F cells as a control; ii) Alpha5 cells, a malignant and tumorigenic cell line; and iii) Tumor2 cells derived from Alpha5 cells injected into nude mice. Secondly, we also used normal, benign and malignant breast specimens obtained from biopsies. The results revealed that the MCF‑10F cells were negative for c‑Ha‑Ras protein expression; however, the Alpha5 and Tumor2 cell lines were positive for c‑Ha‑Ras protein expression. The malignant breast samples were also strongly positive for c‑Ha‑Ras expression. The findings of our study indicate that c‑Ha‑Ras protein expression may be used as a marker to predict the progression of breast cancer; this marker may also ultimately provide non‑surgical treatment options for patients who are at a lower risk.

View Figures

View References

1	Azzopardi JG, Ahmed A and Millis RR: Problems in breast pathology. Major Probl Pathol. 11:i–xvi, 1–466. 1979.PubMed/NCBI
2	Dupont WD and Page DL: Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 312:146–151. 1985. View Article : Google Scholar : PubMed/NCBI
3	Tsuchiya A, Kanno M, Nomizu T, Hatakeyama Y, Kimijima I and Abe R: Clinical characteristics of breast cancer patients with family history. Fukushima J Med Sci. 44:35–41. 1998.PubMed/NCBI
4	De Mascarel I and MacGrogan G: Management of breast epithelial atypia. Ann Pathol. 27:182–194. 2007.(In French). View Article : Google Scholar : PubMed/NCBI
5	de Mascarel I, Debled M, Brouste V, Mauriac L, Sierankowski G, Velasco V, Croce S, Chibon F, Boudeau J, Debant A, et al: Comprehensive prognostic analysis in breast cancer integrating clinical, tumoral, micro-environmental and immunohistochemical criteria. Springerplus. 4:5282015. View Article : Google Scholar : PubMed/NCBI
6	Walker RA, Hanby A, Pinder SE, Thomas J and Ellis IO: National Coordinating Committee for Breast Pathology Research Subgroup: Current issues in diagnostic breast pathology. J Clin Pathol. 65:771–785. 2012. View Article : Google Scholar : PubMed/NCBI
7	Spandidos DA and Agnantis NJ: Human malignant tumours of the breast, as compared to their respective normal tissue, have elevated expression of the Harvey ras oncogene. Anticancer Res. 4:269–272. 1984.PubMed/NCBI
8	Agnantis NJ, Parissi P, Anagnostakis D and Spandidos DA: Comparative study of Harvey-ras oncogene expression with conventional clinicopathologic parameters of breast cancer. Oncology. 43:36–39. 1986. View Article : Google Scholar : PubMed/NCBI
9	Agnantis NJ, Petraki C, Markoulatos P and Spandidos DA: Immunohistochemical study of the ras oncogene expression in human breast lesions. Anticancer Res. 6:1157–1160. 1986.PubMed/NCBI
10	Efremidis AP, Agnantis NJ, Patra F, Papadopoulou C and Spandidos DA: Clinical significance of elevated p21 ras oncogene expression in breast cancer patients. Cancer J. 2:288–291. 1989.
11	Spandidos DA, Yiagnisis M, Papadimitriou K and Field JK: Ras, c-myc, and c-erbB-2 oncoprotein expression in human breast carcinomas. Anticancer Res. 9:1385–1394. 1989.PubMed/NCBI
12	Gruver AM, Portier BP and Tubbs RR: Molecular pathology of breast cancer: The journey from traditional practice toward embracing the complexity of a molecular classification. Arch Pathol Lab Med. 135:544–557. 2011.PubMed/NCBI
13	Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, Kim SI and Park BW: Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast. 21:50–57. 2012. View Article : Google Scholar : PubMed/NCBI
14	Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
15	Lerwill MF: Current practical applications of diagnostic immunohistochemistry in breast pathology. Am J Surg Pathol. 28:1076–1091. 2004. View Article : Google Scholar : PubMed/NCBI
16	Abdel-Fatah TM, Powe DG, Hodi Z, Reis-Filho JS, Lee AH and Ellis IO: Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: Further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol. 32:513–523. 2008. View Article : Google Scholar : PubMed/NCBI
17	Moriya T, Kanomata N, Kozuka Y, Fukumoto M, Iwachido N, Hata S, Takahashi Y, Miura H, Ishida K and Watanabe M: Usefulness of immunohistochemistry for differential diagnosis between benign and malignant breast lesions. Breast Cancer. 16:173–178. 2009. View Article : Google Scholar : PubMed/NCBI
18	Dewar R, Fadare O, Gilmore H and Gown AM: Best practices in diagnostic immunohistochemistry: Myoepithelial markers in breast pathology. Arch Pathol Lab Med. 135:422–429. 2011.PubMed/NCBI
19	Leong AS and Zhuang Z: The changing role of pathology in breast cancer diagnosis and treatment. Pathobiology: Journal of Immunopathology. Mol Cell Biol. 78:99–114. 2011.
20	Omi Y, Yamamoto T, Okamoto T, Obara T and Kobayashi M: A useful immunohistochemical approach to evaluate intraductal proliferative lesions of the breast and to predict their prognosis. Histol Histopathol. 26:79–86. 2011.PubMed/NCBI
21	Candlish W, Kerr IB and Simpson HW: Immunocytochemical demonstration and significance of p21 ras family oncogene product in benign and malignant breast disease. J Pathol. 150:163–167. 1986. View Article : Google Scholar : PubMed/NCBI
22	Going JJ, Anderson TJ and Wyllie AH: Ras p21 in breast tissue: Associations with pathology and cellular localisation. Br J Cancer. 65:45–50. 1992. View Article : Google Scholar : PubMed/NCBI
23	Malumbres M and Barbacid M: RAS oncogenes: The first 30 years. Nat Rev Cancer. 3:459–465. 2003. View Article : Google Scholar : PubMed/NCBI
24	Giltnane JM and Balko JM: Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer. Discov Med. 17:275–283. 2014.PubMed/NCBI
25	Calaf GM and Hei TK: Establishment of a radiation- and estrogen-induced breast cancer model. Carcinogenesis. 21:769–776. 2000. View Article : Google Scholar : PubMed/NCBI
26	Lakhani SR, Ellis IO, Schnitt SJ, Tan PH and van de Vijver MJ: WHO classification of tumors of the breast. International Agency for Research on Cancer. Lyon: 2012.
27	Zhang PL, Calaf G and Russo J: Allele loss and point mutation in codons 12 and 61 of the c-Ha-ras oncogene in carcinogen-transformed human breast epithelial cells. Mol Carcinog. 9:46–56. 1994. View Article : Google Scholar : PubMed/NCBI
28	Calaf G, Zhang P, Alvarado M, Estrada S and Russo J: C-ha-ras enhances the neoplastic transformation of human breast epithelial-cells treated with chemical carcinogens. Int J Oncol. 6:5–11. 1995.PubMed/NCBI
29	Roy D, Calaf G and Hei TK: Allelic imbalance at 11p15.5–15.4 correlated with c-Ha-ras mutation during radiation-induced neoplastic transformation of human breast epithelial cells. Int J Cancer. 103:730–737. 2003. View Article : Google Scholar : PubMed/NCBI
30	Calaf GM and Roy D: Cancer genes induced by malathion and parathion in the presence of estrogen in breast cells. Int J Mol Med. 21:261–268. 2008.PubMed/NCBI